Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QAV680 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| QAV680 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Fluticasone Propionate Inhaler | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| QAV680 | DRUG | - |
| Matching placebo for QAV680 | DRUG | - |
| Fluticasone Propionate | DRUG | - |
| Mometasone Furoate | DRUG | - |
Inclusion criteria: * Mild to moderate persistent asthma for at least 6 months. Exclusion criteria: * Past or recent history of significant medical illness and/or lab abnormalities including but not limited to ECG abnormalities, abnormal LFT, HIV, Hep B/C, * Allergic disorders, pancreatic disease...
QAV680 is an investigational small molecule being developed by Novartis for respiratory conditions, specifically seasonal allergic rhinitis and asthma. It has been studied in Phase 2 clinical trials for these indications.
QAV680 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 2 clinical development.
QAV680 is in Phase 2 clinical development. It has completed two Phase 2 trials, one in seasonal allergic rhinitis and one in asthma. It is not approved and remains investigational.
QAV680 has been studied in two completed Phase 2 trials. NCT00784732 evaluated the drug against placebo in seasonal allergic rhinitis using an environmental exposure chamber in Canada. NCT00814216 assessed efficacy, safety, and pharmacokinetics in asthma patients in Germany and India.
No alternative names for QAV680 have been reported. The drug is identified solely by its code name QAV680 in clinical trial registries and development records.